7TM Pharma adds Johnson & Johnson Development Corp. to its Investor Group

7TM Pharma has expanded its investor base with the inclusion of Johnson & Johnson Development Corporation, JJDC. JJDC's investment in the company, combined with investments from current investors and revenues from collaborative agreements, will be used to advance 7TM Pharma's development and discovery programmes with the focus on metabolic disorders.

7TM Pharma's other investors include Alta Partners, Index Ventures, Novo A/S, Dansk Innovationsinvestering, Lombard Odier Darier Hentsch & Cie, and Baker/Tisch Investment.

7TM Pharma is a drug discovery and development company focusing on medicines that act through 7TM receptors. Members of this receptor family are among the most valuable drug targets for the pharmaceutical industry, with approximately one quarter of all prescription medicines currently in use targeting this class of receptors. The company is tightly integrating its structure based drug discovery approach, Site-Directed Drug Discovery, with traditional medicinal chemistry and expert knowledge on peptides to create a drug discovery platform that dramatically accelerates the generation of new drugs targeting 7TM receptors. The company has entered into several collaborative drug discover partnerships, including agreements with Ortho-McNeil, Inc., Procter & Gamble Pharmaceuticals Inc., H. Lundbeck A/S and AstraZeneca.

For further information please contact:

Mette Kirstine Agger,

CEO

Tel: +45 39 25 77 77

Email: agger@7tm.com